• Vol. 30 No. 5, 542–545
  • 15 September 2001

188Rhenium-TDD-Lipiodol in Treatment of Inoperable Primary Hepatocellular Carcinoma—A Case Report



Introduction: The aim of this study was to investigate the potential of using 188Re Lipiodol for selective internal radiation therapy of inoperable hepatocellular carcinoma (HCC).

Clinical Picture: A 33-year-old female with poorly-differentiated multicentric HCC, elevated alpha-fetoprotein (AFP) and increased serum alkaline phosphatase.

Treatment: Over a 2-month interval, the patient was treated twice with 4GBq of 188Re-TDD-Lipiodol.

Outcomes: There was good localisation of 188Re Lipiodol in the tumours, but also in thyroid (first treatment) and gastrointestinal tract (both treatments). So far (5 months post- treatment), the patient remains well with stable disease.

Conclusions: 188Re Lipiodol can be an effective radiopharmaceutical for the treatment of HCC; however, more work must be done to minimise the uptake in bowel.

Hepatocellular carcinoma (HCC) is one of the most malignant tumours. The lack of an effective treatment modality has stimulated the use of selective internal radiation therapy for the treatment of HCC.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.